Skip Ribbon Commands Skip to main content

Making products better together

With over 25 years in the biopharmaceutical industry, Novozymes Biopharma is dedicated to providing specialized technology solutions and recombinant products such as recombinant albumin and hyaluronic acid, tailored to the needs of the drug delivery and medical device industries. Our customer-integrated approach combines Novozymes Biopharma’s scientific know-how with the specific needs of customers to deliver improved products and performance.
Recombinant albumin and hyaluronic acid are produced in large-scale manufacturing facilities worldwide, which are operated to Q7 cGMP quality standards to ensure the highest level of product quality, consistency, and security of long-term supply.
Our customer focused partnering approach packages our award winning technologies such as half-life extension with over 25 years of scientific, technical and regulatory support to customers for the delivery of improved and better performing products.




March 31, 2014
› Novozymes VELTIS® half-life extension technology used by GlaxoSmithKline in type 2 diabetes drug approved in Europe. Read more

March 13, 2014
› Novozymes Biopharma announces collaboration with Janssen to evaluate proprietary VELTIS half-life extension technology. Read more

January 21, 2014
› Novozymes Biopharma announces new data highlighting potential for monthly drug dosing. Read more

October 22, 2013
› Novozymes Biopharma announces collaboration with Almac in drug manufacture, half-life extension and targeting technologies. Read more

July 18, 2013
› Novozymes Biopharma's Hyasis increases drug release of tramadol hydrochloride from 1.9 to 7.5 hours. Read more


› To view upcoming events click here

Copyright © 2014 Novozymes. All rights reserved.